$TOVX
Theriva Biologics, Inc.

2017 Q2 Form 10-Q Financial Statement

#000114420417040110 Filed on August 03, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.640M $2.150M
YoY Change -23.72% -3.15%
% of Gross Profit
Research & Development $4.831M $7.164M
YoY Change -32.57% -4.58%
% of Gross Profit
Depreciation & Amortization $60.00K $20.00K
YoY Change 200.0% 100.0%
% of Gross Profit
Operating Expenses $6.475M $9.311M
YoY Change -30.46% -4.31%
Operating Profit -$6.475M -$9.311M
YoY Change -30.46% -4.31%
Interest Expense $0.00 $30.00K
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $2.160M $3.547M
YoY Change -39.1% -191.11%
Pretax Income -$6.475M -$9.311M
YoY Change -30.46% -4.31%
Income Tax
% Of Pretax Income
Net Earnings -$4.315M -$5.764M
YoY Change -25.14% -57.69%
Net Earnings / Revenue
Basic Earnings Per Share -$1.05 -$0.06
Diluted Earnings Per Share -$1.05 -$0.10
COMMON SHARES
Basic Shares Outstanding 3.514M 91.02M shares
Diluted Shares Outstanding 3.514M 93.93M shares

Balance Sheet

Concept 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.38M $10.05M
YoY Change 33.13% 111.13%
Cash & Equivalents $13.38M $10.05M
Short-Term Investments
Other Short-Term Assets $1.550M $5.774M
YoY Change -73.16% -16.98%
Inventory
Prepaid Expenses $382.0K
Receivables
Other Receivables $612.0K
Total Short-Term Assets $14.92M $15.82M
YoY Change -5.69% 35.1%
LONG-TERM ASSETS
Property, Plant & Equipment $800.0K $480.0K
YoY Change 66.67% 336.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.00K $30.00K
YoY Change -33.33% 50.0%
Total Long-Term Assets $820.0K $510.0K
YoY Change 60.78% 292.31%
TOTAL ASSETS
Total Short-Term Assets $14.92M $15.82M
Total Long-Term Assets $820.0K $510.0K
Total Assets $15.74M $16.33M
YoY Change -3.61% 37.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.720M $4.560M
YoY Change -62.28% -47.53%
Accrued Expenses $2.960M $3.020M
YoY Change -1.99% 50.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.33M $15.17M
YoY Change -18.72% -40.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $450.0K $230.0K
YoY Change 95.65%
Total Long-Term Liabilities $450.0K $230.0K
YoY Change 95.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.33M $15.17M
Total Long-Term Liabilities $450.0K $230.0K
Total Liabilities $10.91M $15.40M
YoY Change -29.16% -39.61%
SHAREHOLDERS EQUITY
Retained Earnings -$161.3M
YoY Change
Common Stock $163.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.830M $2.294M
YoY Change
Total Liabilities & Shareholders Equity $15.74M $16.33M
YoY Change -3.62% 37.93%

Cashflow Statement

Concept 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income -$4.315M -$5.764M
YoY Change -25.14% -57.69%
Depreciation, Depletion And Amortization $60.00K $20.00K
YoY Change 200.0% 100.0%
Cash From Operating Activities -$5.740M -$5.860M
YoY Change -2.05% -19.17%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K
YoY Change -100.0% -75.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$10.00K
YoY Change -100.0% -75.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.640M 810.0K
YoY Change 596.3%
NET CHANGE
Cash From Operating Activities -5.740M -5.860M
Cash From Investing Activities 0.000 -10.00K
Cash From Financing Activities 5.640M 810.0K
Net Change In Cash -100.0K -5.060M
YoY Change -98.02% -30.59%
FREE CASH FLOW
Cash From Operating Activities -$5.740M -$5.860M
Capital Expenditures $0.00 -$10.00K
Free Cash Flow -$5.740M -$5.850M
YoY Change -1.88% -18.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3734000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10891000 USD
us-gaap Operating Expenses
OperatingExpenses
14625000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-14625000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
3000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7252000 USD
us-gaap Profit Loss
ProfitLoss
-7373000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-272000 USD
us-gaap Profit Loss
ProfitLoss
-16842000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1959000 USD
syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
11000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
143000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1543000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11534000 USD
syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
810000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
810000 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-10769000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20818000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10049000 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3015000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
897000 USD
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-10000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2006000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-975000 USD
syn Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
1000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-270000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11748000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11000 USD
syn Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises
ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises
166000 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-877000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
116000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
5914000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2016Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1700000 USD
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
303000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
186000 USD
CY2017Q2 syn Accrued Vendor Payments
AccruedVendorPayments
249000 USD
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2000 USD
CY2017Q2 syn Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
1129000 USD
CY2017Q2 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
368000 USD
CY2016Q4 syn Accrued Manufacturing Costs
AccruedManufacturingCosts
14000 USD
CY2017Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
842000 USD
CY2016Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
0 USD
CY2017Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
367000 USD
CY2016Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
261000 USD
CY2017Q2 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
0 USD
CY2016Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
52000 USD
CY2017Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1209000 USD
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
313000 USD
CY2017Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4600000 USD
CY2017Q2 us-gaap Share Price
SharePrice
0.57
CY2016Q4 us-gaap Share Price
SharePrice
0.76
CY2016Q4 us-gaap Share Price
SharePrice
1.75
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2016Q4 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.009 pure
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.95 pure
CY2016Q4 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.95 pure
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0143 pure
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0141 pure
CY2016Q4 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0139 pure
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y3M18D
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2017Q2 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.885 pure
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y9M14D
CY2016Q4 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7908899 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
57341642 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
57341642 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
50000000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0 shares
CY2016 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
0 shares
syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
0 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
567257 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.79
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.6
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.6
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2016 syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
syn Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
2.35
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4255000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7101000 USD
CY2017Q2 syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4255000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7101000 USD
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
123005220 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
120241593 shares
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123005220 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
120241593 shares
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
117254196 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
127746096 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
117172714 shares
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93930540 shares
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16842000 USD
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4573000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15319000 USD
us-gaap Operating Expenses
OperatingExpenses
19892000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-19892000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
35000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3050000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-315000 USD
us-gaap Net Income Loss
NetIncomeLoss
-16527000 USD
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90921243 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2017Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
612000 USD
CY2016Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
0 USD
CY2017Q2 us-gaap Prepaid Insurance
PrepaidInsurance
185000 USD
CY2016Q4 us-gaap Prepaid Insurance
PrepaidInsurance
358000 USD
CY2017Q2 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
46000 USD
CY2016Q4 syn Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
1677000 USD
CY2017Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1103000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1091000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5764000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9277000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-19857000 USD
CY2016Q2 syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
syn Dilutive Shares Related To Warrants
DilutiveSharesRelatedToWarrants
0 USD
CY2016Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2914807 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1729974 shares
CY2017Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
200000 USD
CY2017Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
382000 USD
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
295000 USD
CY2017Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
315000 USD
CY2016Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
185000 USD

Files In Submission

Name View Source Status
0001144204-17-040110-index-headers.html Edgar Link pending
0001144204-17-040110-index.html Edgar Link pending
0001144204-17-040110.txt Edgar Link pending
0001144204-17-040110-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pg18img1_10q.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
syn-20170630.xml Edgar Link completed
syn-20170630.xsd Edgar Link pending
syn-20170630_cal.xml Edgar Link unprocessable
syn-20170630_def.xml Edgar Link unprocessable
syn-20170630_lab.xml Edgar Link unprocessable
syn-20170630_pre.xml Edgar Link unprocessable
v471253_10q.htm Edgar Link pending
v471253_ex31-1.htm Edgar Link pending
v471253_ex31-2.htm Edgar Link pending
v471253_ex32-1.htm Edgar Link pending
v471253_ex32-2.htm Edgar Link pending